These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 19531628)
1. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Sem M; Molberg O; Lund MB; Gran JT Rheumatology (Oxford); 2009 Aug; 48(8):968-71. PubMed ID: 19531628 [TBL] [Abstract][Full Text] [Related]
2. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830 [TBL] [Abstract][Full Text] [Related]
3. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Tillie-Leblond I; Wislez M; Valeyre D; Crestani B; Rabbat A; Israel-Biet D; Humbert M; Couderc LJ; Wallaert B; Cadranel J Thorax; 2008 Jan; 63(1):53-9. PubMed ID: 17557770 [TBL] [Abstract][Full Text] [Related]
4. Effects of rituximab on resistant SLE disease including lung involvement. Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171 [TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease in polymyositis and dermatomyositis. Marie I; Hachulla E; Chérin P; Dominique S; Hatron PY; Hellot MF; Devulder B; Herson S; Levesque H; Courtois H Arthritis Rheum; 2002 Dec; 47(6):614-22. PubMed ID: 12522835 [TBL] [Abstract][Full Text] [Related]
8. Rituximab for refractory polymyositis: an open-label prospective study. Mok CC; Ho LY; To CH J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224 [TBL] [Abstract][Full Text] [Related]
9. Rituximab in life threatening antisynthetase syndrome. Vandenbroucke E; Grutters JC; Altenburg J; Boersma WG; ter Borg EJ; van den Bosch JM Rheumatol Int; 2009 Oct; 29(12):1499-502. PubMed ID: 19184665 [TBL] [Abstract][Full Text] [Related]
10. Refractory anti-synthetase syndrome treated with rituximab. Ball EM; Savage EM; Pendleton A Rheumatology (Oxford); 2010 May; 49(5):1013. PubMed ID: 20032227 [No Abstract] [Full Text] [Related]
11. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Marie I; Dominique S; Janvresse A; Levesque H; Menard JF Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877 [TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384 [TBL] [Abstract][Full Text] [Related]
13. [The anti-Jo-1 syndrome - a specific form of myositis with interstitial lung disease]. Häussermann A; Gillissen A; Seidel W Pneumologie; 2010 Aug; 64(8):496-503. PubMed ID: 20387195 [TBL] [Abstract][Full Text] [Related]
14. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X; Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome]. Franzolini N; Quartuccio L; De Marchi G; De Vita S Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879 [TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Life-Threatening Interstitial Lung Disease Secondary to Antisynthetase Syndrome Using Rituximab: A Case Report and Review of the Literature. Dasa O; Ruzieh M; Oraibi O Am J Ther; 2016; 23(2):e639-45. PubMed ID: 25830868 [TBL] [Abstract][Full Text] [Related]
20. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]